DMAC - CIK 0001401040
The table below shows DiaMedica Therapeutics Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $24.61M | $19.06M | $13.11M | $7.84M | $8.77M | $8.21M |
| SG&A | $9.78M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $7.62M |
| $8.16M |
| $6.16M |
| $4.88M |
| $4.49M |
| Operating income | -$34.40M | -$26.68M | -$21.27M | -$14.00M | -$13.65M | -$12.70M |
| Income tax | $28.00K | $30.00K | $43.00K | $28.00K | $28.00K | $27.00K |
| Net income | -$32.77M | -$24.44M | -$19.38M | -$13.68M | -$13.59M | -$12.29M |
| EPS (diluted) | - | - | - | - | - | - |